Trump sets tariff deadline for Russia to end war in Ukraine
Trump made the announcement of what he said would be a 100 per cent tariff rate while meeting with reporters alongside NATO Secretary General Mark Rutte in the Oval Office in Washington, D.C.
Trump also said the United States will send military aid to help Ukraine in its war effort, but that NATO members, not American taxpayers, would cover the cost of the weapons.
"We're going to make top-of-the-line weapons, and they'll be sent to NATO," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
39 minutes ago
- Globe and Mail
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
"Multiple System Atrophy Clinical Trials" Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others. (Albany, United States) 'Multiple System Atrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market. As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details Request for sample report to know in detail about drugs and companies in pipeline @ Multiple System Atrophy Pipeline Outlook Some of the key takeaways from the Multiple System Atrophy Pipeline Report: Multiple System Atrophy Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years. Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years. are expected to have a significant impact on the Multiple System Atrophy market in the coming years. In May 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy. In February 2025, H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA). In December 2024, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on creating disease-modifying therapies for neurodegenerative disorders, announced that the final participant in its ATH434-201 Phase 2 trial has completed the study. This randomized, double-blind, placebo-controlled trial targets early-stage multiple system atrophy (MSA). With this milestone reached, topline results are anticipated by late January or early February 2025. Multiple System Atrophy Overview Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by Multiple System Atrophy autonomic dysfunction, Multiple System Atrophy parkinsonism, and Multiple System Atrophy cerebellar ataxia. Multiple System Atrophy symptoms often include orthostatic hypotension, urinary incontinence, tremors, bradykinesia, muscle rigidity, gait imbalance, and coordination problems. Multiple System Atrophy diagnosis typically relies on clinical evaluation supported by MRI findings, which may show putaminal or cerebellar atrophy, although no definitive test exists. Multiple System Atrophy pathology reveals glial cytoplasmic inclusions containing alpha-synuclein, distinguishing it from similar disorders. Multiple System Atrophy progression is usually rapid, leading to severe disability within a few years of onset. Multiple System Atrophy treatment remains symptomatic, aiming to manage blood pressure fluctuations, motor symptoms, and urinary issues. While Multiple System Atrophy levodopa responsiveness is often poor compared to Parkinson's disease, some patients may experience temporary benefit. Multiple System Atrophy prognosis is generally poor, with an average survival of 6 to 10 years post-diagnosis. Ongoing Multiple System Atrophy research explores neuroprotective agents and disease-modifying therapies. Multiple System Atrophy awareness is essential for early recognition and multidisciplinary care to optimize patient quality of life. Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment- Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include: NM-402: Neuramedy Co.,Ltd Neuramedy Co.,Ltd PMN442: ProMIS Neurosciences ProMIS Neurosciences ENT-01: Enterin Inc. Enterin Inc. NC-2500: Nippon Chemiphar Nippon Chemiphar CS10BR05: CORESTEM, Inc CORESTEM, Inc AAV2-GDNF: Brain Neurotherapy Bio, Inc. Brain Neurotherapy Bio, Inc. KM-819: Kainos Medicines Kainos Medicines ATH434: Alterity Therapeutics Alterity Therapeutics Lu AF82422: H. Lundbeck A/S H. Lundbeck A/S Verdiperstat: Biohaven, Ltd Biohaven, Ltd Ampreloxetine: Selecta Biosciences Inc Selecta Biosciences Inc ION464: Ionis Pharmaceuticals, Inc Multiple System Atrophy Route of Administration Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Multiple System Atrophy Molecule Type Multiple System Atrophy Products have been categorized under various Molecule types, such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Multiple System Atrophy Pipeline Therapeutics Assessment Multiple System Atrophy Assessment by Product Type Multiple System Atrophy By Stage and Product Type Multiple System Atrophy Assessment by Route of Administration Multiple System Atrophy By Stage and Route of Administration Multiple System Atrophy Assessment by Molecule Type Multiple System Atrophy by Stage and Molecule Type DelveInsight's Multiple System Atrophy Report covers around 22+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies Some of the key companies in the Multiple System Atrophy Therapeutics Market include: Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others. Multiple System Atrophy Pipeline Analysis: The Multiple System Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment. Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies Multiple System Atrophy Pipeline Market Drivers Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market. Multiple System Atrophy Pipeline Market Barriers However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth. Scope of Multiple System Atrophy Pipeline Drug Insight Coverage: Global Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials Table of Contents 1. Multiple System Atrophy Report Introduction 2. Multiple System Atrophy Executive Summary 3. Multiple System Atrophy Overview 4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment 5. Multiple System Atrophy Pipeline Therapeutics 6. Multiple System Atrophy Late Stage Products (Phase II/III) 7. Multiple System Atrophy Mid Stage Products (Phase II) 8. Multiple System Atrophy Early Stage Products (Phase I) 9. Multiple System Atrophy Preclinical Stage Products 10. Multiple System Atrophy Therapeutics Assessment 11. Multiple System Atrophy Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Multiple System Atrophy Key Companies 14. Multiple System Atrophy Key Products 15. Multiple System Atrophy Unmet Needs 16 . Multiple System Atrophy Market Drivers and Barriers 17. Multiple System Atrophy Future Perspectives and Conclusion 18. Multiple System Atrophy Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
CBC
40 minutes ago
- CBC
Trump pivots almost '180 degrees' on Ukraine after Putin 'embarrassed him': Bremmer
As U.S. President Donald Trump threatens Russia with 100 per cent secondary tariffs and says the U.S. will allow European allies to buy Patriot missile defence systems for Ukraine, Eurasia Group president Ian Bremmer argues Trump has changed his stance on the war more than any other aspect of his foreign policy.
Toronto Sun
an hour ago
- Toronto Sun
LILLEY UNLEASHED: No deals with the Donald yet for Mark Carney
WASHINGTON, DC - JULY 13: U.S. President Donald Trump walks on the south lawn of the White House and points up at the new flag on July 13, 2025 in Washington, DC. President Trump and first lady Melania Trump spend the afternoon attending the final match of the FIFA Club World Cup at MetLife Stadium in East Rutherford, New Jersey. (Photo by) WATCH: As the threat of tariffs continues,Sun political columnist Brian Lilley asks – where is the deal between Canada and the U.S.? What do YOU think? Tell us your thoughts in the comment section below or send us a Letter to the Editor for possible publication to . Letters must be 250 words or less and signed. And don't forget to subscribe to our YouTube Channel. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Columnists NFL NHL Golf World
